Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investment strategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Lux Capital

IA Ventures is a venture capital firm that specializes in seed-stage investments in the fintech sector.  The firm seeks to invest in companies operating in information technology, e-commerce, software, financial services, healthcare, media, big data, and business services sectors.

IA Ventures

Amplo is a global venture capital firm helping build companies that matter. It specializes in the fields of financial services, venture capital and financial exchanges. Amplo was founded in 2017 and headquartered in Spring, Texas.

Amplo

Springbank Collective is an early-stage investment firm that focuses on the infrastructure that supports women and working families. The firm typically invests in seed and series A with check sizes between $250k and $1M. Springbank Collective was founded in 2019 and is based in New York.

Springbank Collective

Maveron is a consumer-only venture capital firm. Founded in 1998 by Dan Levitan and Howard Schultz, the firm has offices in San Francisco and Seattle. Maveron investments include Zulily, Allbirds, Common, August Home, eBay, Capella Education, General Assembly, and Trupanion. Maveron's name was coined from the words ''maverick'' and ''vision.'' Maveron funds seed and Series A companies that empower consumers to live on their terms. Based in SF and Seattle and invest coast-to-coast. Maveron has adopted the Diversity Term Sheet Rider.

Maveron

Union Square Ventures is a private equity and venture capital firm focused on early-stage, growth capital, late-stage, and startup financing. The USV portfolio companies create services that have the potential to fundamentally transform important markets.  It exclusively invests in the internet world, focusing on the applications layer of the web, internet services, and web services that create large networks as well as the mobile sector. Some of its invested companies are based in New York, San Francisco, London, Berlin, and places in between. It typically makes a starting investment in portfolio companies of $1 million. In certain Series Around cases, the firm may make a starting investment between $2.5 million to $3 million. It typically invests up to $20 million in any single company. Union Square Ventures was founded in 2003 and is based in New York, United States.

Union Square Ventures

Farvatn Venture is a new San Francisco based venture capital firm that invest early stage in the most promising emerging tech companies.

Farvatn Venture

Alife

Alife develops artificial intelligence tools to assist physicians in increasing a patient's chances of pregnancy success. The company has a mission of helping people have healthy children and connects fertility specialists to patients to assists with IVF. Alife Health was founded in 2020 by Paxton Maeder-York and is headquartered in San Francisco, California, United States.

<div>Alife Health develops AI tools to improve fertility and reproductive health. The company applies AI to improving in vitro fertilization (IVF) to enable clinical decision-making with personalized treatment recommendations (such as the number of embryos to bank). Alife&rsquo;s AI tools use a range of information to provide personalized recommendations&mdash;including racial and ethnic data&mdash;to reduce risks, and optimize the chances of successful fertilization.</div>

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Alife Health is a fertility technology company that develops artificial intelligence (AI) tools to optimize and support clinical decision-making throughout the in-vitro fertilization (IVF) process. The company's cutting-edge technology leverages machine learning algorithms and data analytics to provide personalized insights and recommendations, with the aim of improving outcomes and care for patients undergoing IVF treatment.

Alife Health Partners with Ovation Fertility on Cutting-Edge AI Technology for Embryo Image Capture and Cataloguing

Alife Health raises $22M series A for fertility AI tools

Alife Announces its $22 Million Series A to Modernize and Personalize Fertility Care with Artificial Intelligence

Innovation Fertility Partners with Alife Health to Bring AI to IVF Clinics Around the Country

AI-enabled fertility company Alife scores $9.5M in Seed funding

Alife Launches New AI Platform to Optimize IVF

AI-enabled fertility company Alife Health scores $22M

Investing in Alife Health: AI Takes on the Fertility Crisis

Alife Raises $22M to Advance In-Vitro Fertilization Through AI

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Alife Health

Alife Health Partners with US Fertility to Pilot Embryology Laboratory AI Tools

US Fertility

To enhance IVF laboratory operations and provide patients with greater insight into their embryology processes through the integration of Alife's AI-powered Embryo Assist software.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

<div>
 
 Alife Health develops AI tools to improve fertility and reproductive health. The company applies AI to improving in vitro fertilization (IVF) to enable clinical decision-making with personalized treatment recommendations (such as the number of embryos to bank). Alife&rsquo;s AI tools use a range of information to provide personalized recommendations&mdash;including racial and ethnic data&mdash;to reduce risks, and optimize the chances of successful fertilization.
 
 
 Stim Assist is an AI tool used during ovarian simulations&mdash;a procedure where patients receive injected medications that stimulate the ovaries to produce and release mature eggs. This provides clinicians with insights that support their decision-making in utilizing the correct dose of medication to retrieve the maximum number of mature eggs per cycle from the patient for fertilization and implantation while reducing medication costs. Alife's mobile app is its first B2C platform, which it plans to launch later in 2022. The app will feature educational resources and tools for medication reminders, appointments, lab results, and more. Embryo Predict is an AI-based solution that helps embryologists in analyzing and transferring patient embryos.
 
 
 As of May 2021, Alife Health had an employee headcount of 11.
 
 
 In March 2022, the company 
 <a href="https://sp-edge.com/updates/9300?industryIds=40">
 raised USD 22 million
 </a>
 in a Series A funding round co-led by Deena Shakir (Lux Capital), Rebecca Kaden (Union Square Ventures), and Anarghya Vardhana (Maveron). The funds were expected to be used to launch its two fertility products (Stim Assist and Alife mobile app) to the market and conduct clinical trials for its third fertility product (Embryo Predict), which is still under development.
 
</div>

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

Alife Health is a fertility technology company that develops artificial intelligence (AI) tools to optimize and support clinical decision-making throughout the in-vitro fertilization (IVF) process. The company's cutting-edge technology leverages machine learning algorithms and data analytics to provide personalized insights and recommendations, with the aim of improving outcomes and care for patients undergoing IVF treatment.
Alife's flagship product, Alife Assist, is a suite of tools that streamlines and enhances various stages of the IVF journey. Stim Assist, one of its key offerings, utilizes AI to guide clinicians in determining the optimal medication dosage and timing during ovarian stimulation, maximizing the number of mature eggs retrieved per cycle. Embryo Assist, another component, enables embryologists to capture, grade, organize, and report embryo data digitally, streamlining workflow and ensuring consistency.
Beyond clinical decision support, Alife Health also offers Insights, an analytics dashboard that provides real-time monitoring and visualization of clinic performance metrics, facilitating operational optimization. Additionally, the company plans to launch a patient-facing mobile app in 2022, designed to provide educational resources and organizational tools for medication reminders, appointments, and lab results.
Established in 2020 and headquartered in San Francisco, Alife Health has forged partnerships with leading fertility clinics and renowned physicians, leveraging one of the largest and most diverse IVF datasets to drive its AI models. As of March 2022, the company had raised USD 31.5 million in venture capital funding from investors such as Lux Capital, Union Square Ventures, and Maveron.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

PROMINENT_CATEGORY

<div>
 Alife Health, an AI technology firm specializing in IVF, has entered into a partnership with US Fertility, a leading network of physician-owned fertility practices. The collaboration aims to bolster IVF laboratory procedures and afford patients deepened understanding of their embryology processes, thanks to Alife's AI-driven Embryo Assist software.
 
 The Embryo Assist software by Alife, interoperable with laboratory microscopes, facilitates the capturing of embryo pictures and related data thus bolstering quality control and enabling real-time laboratory updates. US Fertility, which carries out in excess of 50,000 IVF retrieval cycles yearly by 200 physicians all over the nation, aims to optimize laboratory procedures and offer patients an enhanced understanding of their IVF journey.
 
</div>

Alife Health

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless